Oncept IL-2: Feline Fibrosarcoma Immunotherapy and EU Label Profile

feline interleukin-2 recombinant canarypox virus (vCP1338) is covered as veterinary biologic immunotherapy used with surgery and radiotherapy, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Veterinary biologic immunotherapy used with surgery and radiotherapy. Live canarypox virus strain vCP1338 expressing the feline interleukin-2 gene.

Live canarypox virus strain vCP1338 expressing the feline interleukin-2 gene.

The non-replicating vector is used to deliver feline interleukin-2 locally around the surgically treated tumour bed, with the aim of stimulating local antitumour immunity while limiting systemic interleukin-2 exposure. The mechanism does not substitute for tumour excision or radiotherapy.

The current European product information limits the labelled context to cats with fibrosarcoma meeting defined size and staging criteria, without metastasis or lymph-node involvement, and uses Oncept IL-2 in addition to surgery and radiotherapy. It is not the canine Oncept melanoma DNA vaccine and the two products must never share a page or product identity.

The current European product information limits the labelled context to cats with fibrosarcoma meeting defined size and staging criteria, without metastasis or lymph-node involvement, and uses Oncept IL-2 in addition to surgery and radiotherapy. It is not the canine Oncept melanoma DNA vaccine and the two products must never share a page or product identity.

Reconstituted suspension administered by veterinary subcutaneous injection around the tumour bed

EMA assessment documents and the current Union Product Database describe an authorised product and the trial-supported recurrence endpoint within the labelled multimodal setting. Evidence was generated with surgery and radiotherapy; it should not be extrapolated to stand-alone use, metastatic disease, other sarcoma types or repeated courses without a veterinary benefit-risk assessment.

Current product information describes local reactions such as pain on palpation, swelling or scratching and provides administration and handling warnings. Live-vector handling, reconstitution, injection placement, storage and disposal belong to the veterinary team. A recurrence, wound problem or systemic illness needs reassessment rather than an unplanned repeat course.

Because effectiveness was tested with surgery and radiotherapy, timing and coordination with those modalities matter. Concurrent immunosuppression, active infection, poor wound healing, metastasis, lymph-node disease or a tumour outside the label population may change eligibility and requires specialist review.

The EU Union Product Database listed the central marketing authorisation as valid when checked on 12 August 2026. The VMD current-product list separately showed Oncept IL-2 authorised in Great Britain as POM-V under VM number 04491/5039. An older Great Britain record expired on 30 June 2026, but it must not be mistaken for the current authorisation.

Current authorisation was verified for the EU/EEA, Northern Ireland under the EU record, and Great Britain under the cited VMD record. Regional product information remains distinct. No United States or Australian authorisation is asserted.

The oncology team should confirm histopathology, tumour dimensions, margins, staging and the radiotherapy plan before deciding whether the label population applies. Records should keep the exact product, batch, storage history and administration dates, then track local reactions, wound healing and recurrence surveillance. This Directory profile does not reproduce a dosing calendar.